Ligand to Report First Quarter Results on May 5th

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2010 financial results on Wednesday, May 5, 2010, following the close of market. Ligand’s President and CEO, John L. Higgins and Vice President of Finance and CFO, John Sharp will host the conference call.

First Quarter Earnings Call

What:   Ligand Pharmaceuticals conference call to discuss financial results and provide general business updates.
 
When: Wednesday, May 5, 2010
 
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
 
Webcast:

Conference call and replay accessible at www.ligand.com.

 
Conference Call: (877) 407-4019, passcode: Ligand
(201) 689-8337 outside the U.S.
 
Replay: (877) 660-6853, Account #: 361 passcode: 349820
(201) 612-7415 outside the U.S.

About Ligand Pharmaceuticals

Ligand discovers and develops new drugs that address critical unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, Alzheimer's, inflammatory diseases, anemia, COPD, asthma, rheumatoid arthritis and osteoporosis. Ligand's proprietary drug discovery and development programs are based on advanced cell-based assays, gene-expression tools, ultra-high throughput screening and one of the world's largest combinatorial chemical libraries. Ligand has strategic alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Bristol-Myers Squibb, and Cephalon and more than 30 programs are in various stages of development by its partners.



CONTACT:

Ligand Pharmaceuticals Incorporated
John L. Higgins, President and CEO
or
Erika Luib, Investor Relations
(858) 550-7896
or
Lippert/Heilshorn & Associates
Don Markley
(310) 691-7100
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me